Artificial Axon Labs

Artificial Axon Labs is an early-stage biotech founded in 2021, originating from MIT research, that is building a novel drug discovery platform. The company's core innovation is the 'Artificial Axons' assay, which uses advanced 3D printing to create axon-like structures, enabling direct, high-throughput quantification of myelination by human cells in a brain-mimetic environment. This platform aims to overcome the limitations of animal models and traditional 2D assays to identify promising drug candidates for demyelinating diseases like MS. The company is pre-revenue, has won several grants and awards, and is advancing its platform validation and early drug discovery efforts.

Proprietary 'Artificial Axons' platform combining high-resolution 3D printing of sub-micrometer axon mimics with patient-derived human cells to enable direct, quantitative measurement of myelination for drug discovery and disease modeling.

Competes with other biotechs pursuing remyelination therapies (e.g., via stem cells or growth factors) and with broader CNS drug discovery platforms. Its differentiation lies in the direct, 3D, human-cell-based myelination readout, a unique approach not offered by standard 2D assays or animal models.